Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

French court backs class action against Sanofi over Depakine drug

Published 01/05/2022, 05:52 AM
Updated 01/05/2022, 07:00 AM
© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine, France, August 6, 2019. REUTERS/Charles Platiau

© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine, France, August 6, 2019. REUTERS/Charles Platiau

By Tangi Salaün

PARIS (Reuters) -A French court ruled on Wednesday that families of victims of Depakine, an epilepsy drug that caused birth defects and learning difficulties when taken during pregnancy, could join a class action lawsuit against drugmaker Sanofi (NASDAQ:SNY).

Sanofi said it would appeal against the decision.

"This is a great victory. This decision acknowledges the responsibility of the laboratory," Marine Martin, head of victims association APESAC, told Reuters.

APESAC, which represents 7,500 families, launched the class action in September 2021 against Sanofi, which was placed under formal investigation in 2020 on charges of manslaughter over Depakine https://www.reuters.com/article/us-sanofi-depakine-idUSKBN24Z14C.

Sanofi denied those charges at the time and said it would challenge the merits of the investigation.

It said on Wednesday the decision of the court, the Tribunal Judiciaire de Paris, contradicted previous ones in this case.

"The laboratory will appeal this decision. It is partly based on questionable conclusions of an expert's report submitted during the criminal proceedings," the drugmaker said in a statement.

French health authorities have estimated Depakine was responsible for deformities in between 2,150 and 4,100 children and neuro-developmental defects in up to 30,400 children.

© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine, France, August 6, 2019. REUTERS/Charles Platiau

The class action would be a first in France's health sector. APESAC has said families could obtain hundreds of millions of euros in compensation.

Sanofi's shares were up 0.67% at 88.66 euros at 1130 GMT, compared with a 0.5% rise on France's benchmark CAC 40.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.